The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus

Author： Shankar Hari Bichoupan Kian Dieterich Douglas T

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.12, 2013-12, pp. : 1647-1657

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Boceprevir a valuable addition for hepatitis C

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 643, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 312-318

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging targets in the treatment of hepatitis C virus infection

By Le H.V. Yao N. Weber P.C.

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 2, 1998-12 ,pp. : 125-136

Informa Healthcare

Access to resources Recommend Favorite

ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Current Medicinal Chemistry, Vol. 21, Iss. 28, 2014-09 ,pp. : 3261-3270

Bentham Science Publishers

Access to resources Recommend Favorite

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection

By Herbst D Alan Reddy K Rajender

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite